Company news

AstraZeneca PLC news in 2018

AstraZeneca PLC's news releases, calls and decks from 2018, newest first.

View company

Bevespi Aerosphere approved in the EU for COPD

December 20, 2018

Lynparza meets primary endpoint in SOLO-3 trial

December 20, 2018

Phase III ROCKIES and OLYMPUS roxadustat trials

December 20, 2018

FDA approves Lynparza as 1L maintenance therapy

December 19, 2018

Update on the Phase III EAGLE trial of Imfinzi

December 7, 2018

Divestment of rights to Covis completed

December 6, 2018

Grünenthal Agreement for Nexium, Vimovo Completed

December 3, 2018

US FDA grants Fasenra ODD for EGPA

November 26, 2018

AstraZeneca provides update on Phase III MYSTIC

November 16, 2018

AstraZeneca to divest US Synagis rights to Sobi

November 13, 2018

US FDA accepts regulatory submission for Lynparza

November 12, 2018

Farxiga significantly reduced hospitalisation for

November 12, 2018

AZN: Year-to-Date and Q3 2018 Results

November 8, 2018

Divestment of rights to Covis Pharma

November 6, 2018

Additional financial information-Grünenthal deal

October 31, 2018

Grünenthal Agreement for rights to Nexium, Vimovo

October 30, 2018

AstraZeneca Extends Innate Pharma Collaboration

October 23, 2018

Lynparza shows 70% reduction in PFS ovarian cancer

October 22, 2018

CHMP positive opinion Bevespi Aerosphere

October 19, 2018

FDA Orphan Drug for Lynparza in pancreatic cancer

October 16, 2018

Atacand Agreement with Cheplapharm Completed

October 1, 2018

Previous Announcement Regarding Appointment Of NED

September 28, 2018

Overall survival data for Imfinzi: Stage III NSCLC

September 25, 2018

EMA approves AZ's Imfinzi for Stage III NSCLC

September 24, 2018

Farxiga gets positive result in DECLARE-TIMI 58

September 24, 2018

FDA approves AZ's Lumoxiti in hairy cell leukaemia

September 14, 2018

Tezepelumab FDA Breakthrough Therapy Designation

September 7, 2018

AstraZeneca Update on Anifrolumab in SLE

August 31, 2018

EC approves Bydureon BCise device for T2 diabetes

August 30, 2018

AstraZeneca PIIIb trial update for Bevespi in COPD

August 23, 2018

AZ's Tagrisso approved in Japan for 1st-line NSCLC

August 21, 2018

EMA grants OD for selumetinib in NF1

August 3, 2018

CHMP recommends Imfinzi for Stage III nsclc

July 27, 2018

AZN: H1 2018 Results

July 26, 2018

Atacand to be divested to Cheplapharm in Europe

July 24, 2018

Lynparza approved in Japan for BRCAm breast cancer

July 2, 2018

Imfinzi approved in Japan for Stage III nsclc

July 2, 2018

Bydureon receives positive CHMP opinion for BCise

June 29, 2018

AZ and Luye Pharma complete agreement for Seroquel

June 28, 2018

Lynparza: significant PFS 1st-line ovarian cancer

June 27, 2018

Update: lanabecestat Phase III Alzheimer's trials

June 12, 2018

EU approves Tagrisso for 1st-line NSCLC

June 8, 2018

Update on TERRANOVA PIII trial for Fasenra in COPD

May 30, 2018

AZ's Imfinzi: significant OS in Stage III nsclc

May 25, 2018

US FDA approves Lokelma for adult hyperkalaemia

May 21, 2018

AZ regulatory submission in Japan for Forxiga

May 21, 2018

AZN: Q1 2018 Results

May 18, 2018

AstraZeneca update on Fasenra PIII trial in COPD

May 11, 2018

EMA approves Lynparza: maintenance ovarian cancer

May 8, 2018

AZ and Luye Pharma enter agreement for Seroquel

May 8, 2018

Older news releases →

Decks in 2018